Evidence map›Paper›PMID 29794828›Full record

Trial reportAIDS (London, England)2018

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide.

Paul E Sax, Edwin DeJesus, Gordon Crofoot, Douglas Ward, Paul Benson, Robin Dretler, Anthony Mills, Cynthia Brinson, Xuelian Wei, Sean E Collins and 1 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in AIDS (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02397694 (A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02397694 phase2completednot on this map

A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

TypeinterventionalSponsorGilead SciencesRan2015 to 2019Enrolled98ConditionsHIV-1 InfectionArmsBIC, F/TAF, DTG, BIC Placebo, DTG Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Paul E SaxDivision of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Edwin DeJesusOrlando Immunology Center, Orlando, Florida.
Gordon CrofootCrofoot Research Center, Houston, Texas.
Douglas WardDupont Circle Physicians, Washington, District of Columbia.
Paul BensonBe Well Medical, Berkley, Michigan.
Robin DretlerInfectious Disease Specialists of Atlanta, Atlanta, Georgia.
Anthony MillsSouthern California Men's Medical Group, Los Angeles, California.
Cynthia BrinsonCentral Texas Clinical Research, Austin, Texas.
Xuelian WeiGilead Sciences, Foster City, California, USA.
Sean E CollinsGilead Sciences, Foster City, California, USA.
Andrew ChengGilead Sciences, Foster City, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

: A phase 2, randomized, active-controlled study of initial antiretroviral therapy with bictegravir or dolutegravir in combination with emtricitabine and tenofovir alafenamide showed excellent efficacy. After 60 weeks of blinded treatment, participants switched to a single-tablet regimen of bictegravir, emtricitabine, and tenofovir alafenamide. Switching maintained viral suppression in all participants who remained on the study through 12 weeks in the open-label phase, and was safe and well tolerated.

Indexed as

Drug SubstitutionAdministration, OralAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDouble-Blind MethodDrug CombinationsFemaleHIV InfectionsHumansMaleSustained Virologic ResponseTabletsTreatment OutcomeAnti-HIV AgentsDrug CombinationsTablets

Identifiers

PMID29794828
PMCPMC6082593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.